ライフサイエンスコーパス: hypercoagulability

1 on and scalenectomy for SVT as those without hypercoagulability.

2 vein patency was similar to patients without hypercoagulability.

3 specially clear in those patients with known hypercoagulability.

4 he presence of any of the acquired causes of hypercoagulability.

5 ansplant candidates with Fabry's disease for hypercoagulability.

6 group, and comorbid conditions suggestive of hypercoagulability.

7 ignificant comorbid conditions suggestive of hypercoagulability.

8 Recurrent pregnancy loss may result from hypercoagulability.

9 ent decreases in endothelial cell injury and hypercoagulability.

10 outside-in signaling, ultimately leading to hypercoagulability.

11 didates with Fabry's disease were tested for hypercoagulability, analyzed for HLA-type and ABO group,

12 rther supporting an independent link between hypercoagulability and cancer survival.

13 Hypercoagulability and cardiovascular pathology were onl

14 cell disease (SCD) contributes to a state of hypercoagulability and confers a risk of thromboembolic

15 s with T2D had a much greater propensity for hypercoagulability and for amyloidogenesis, and that the

16 Acute lung injury is characterized by hypercoagulability and impaired fibrinolysis.

17 ibitor-1 (PAI-1) in mediating stress-induced hypercoagulability and thrombosis.

18 ysiological characteristics of inflammation, hypercoagulability, and endothelial injury.

19 naemia, compensatory haemopoietic expansion, hypercoagulability, and increased intestinal iron absorp

20 nduces platelet aggregation, correlates with hypercoagulability, and is associated with increased ris

21 The association between arch plaques and hypercoagulability, and its effect on the stroke risk, w

22 ial cells, plug the microvasculature, induce hypercoagulability, and promote infarct expansion.

23 er characterized by intravascular hemolysis, hypercoagulability, and relative bone marrow failure [1]

24 osis, complete reendothelialization, reduced hypercoagulability, and restoration of the vasodilatory

25 uding inflammation, endothelial dysfunction, hypercoagulability, and sympathetic hyperactivity.

26 osteocyte and/or endothelial cell apoptosis, hypercoagulability, and vasoconstriction of specific art

27 effectively improved neointimal hyperplasia, hypercoagulability, and vasoreactivity.

28 mechanisms that apparently contribute to the hypercoagulability associated with cancer.

29 ted for traumatic injury or surgery; (3) had hypercoagulability at admission; or (4) received therape

30 in one of the more common causes of acquired hypercoagulability, both in patients with systemic lupus

31 Patients with hypercoagulability do as well with first rib resection a

32 uld be used with caution in cases with known hypercoagulability, excessive bleeding in the setting of

33 Numerous new factors associated with hypercoagulability have been described in the past few y

34 Patients are tested for hypercoagulability if they present with a spontaneous cl

35 the possible value of quantifying indices of hypercoagulability in clinical practice.

36 his study was to determine the prevalence of hypercoagulability in patients undergoing first rib rese

37 n the predictive value of various markers of hypercoagulability in patients with heart failure, the a

38 Evaluation of inherited hypercoagulability in patients with venous thromboemboli

39 re associated with impaired fibrinolysis and hypercoagulability in subjects with normal glucose toler

40 Hypercoagulability in such women may therefore be due to

41 A major mechanism of hypercoagulability in the antiphospholipid syndrome (APS

42 s that autoantibodies directly contribute to hypercoagulability in the antiphospholipid syndrome (APS

43 This is supported by the presence of hypercoagulability, increased CD61 and CD62P on resting

44 Hypercoagulability increases risk of thrombi that cause

45 oexistence of large aortic plaques and blood hypercoagulability is associated with an increased risk

46 The term "hypercoagulability" is used to describe patients who are

47 However, these patients also have a form of hypercoagulability, manifested primarily by high fibrino

48 whether these and other potential markers of hypercoagulability may help to identify cancer patients

49 Postarrest hypercoagulability of blood seems to yield to therapeuti

50 Thus, the effects of blood flow stasis, hypercoagulability of blood, and the characteristics of

51 The hypercoagulability of pregnancy is present as early as t

52 Our goal was to assess the effect of hypercoagulability on the risk of stroke in patients wit

53 ssociated with gene polymorphisms that cause hypercoagulability or increased platelet stickiness was

54 e majority, a recognized genetic tendency to hypercoagulability or platelet stickiness does not under

55 stroke (OR, 4.43; CI, 3.05-6.42; P < 0.001), hypercoagulability (OR, 2.90; CI, 1.56-5.39; P < 0.001),

56 an extensive laboratory thrombophilia (i.e., hypercoagulability) panel at the time of diagnosis in 14

57 Whether hypercoagulability predisposes for malignancy or the con

58 for all three scenarios were the presence of hypercoagulability, prior deep venous thrombosis, or a c

59 enal transplant candidates were screened for hypercoagulability risk factors [HRF] (multiple arteriov

60 pectively detected in 10 study patients with hypercoagulability risk factors.

61 by both an increased risk of bleeding and a hypercoagulability state, as seen in the patient populat

62 rge aortic plaques are associated with blood hypercoagulability, suggesting a role for coagulation ac

63 nduced thrombocytopenia leads to an acquired hypercoagulability syndrome.

64 , patients were retrospectively reviewed for hypercoagulability testing and clinical outcomes.

65 ) are associated with a clinical syndrome of hypercoagulability, thrombocytopenia, and fetal loss.

66 Pregnancy is an example of Virchow's triad: hypercoagulability, venous stasis, and vascular damage;

67 The main reason for the increased risk is hypercoagulability, which has likely evolved to protect

68 Their relationship with blood hypercoagulability, which might enhance their embolic po

69 by warfarin fails to block cancer-associated hypercoagulability while nonetheless contributing to sev